Novo Nordisk Gets Approval For Hemophilia B Treatment Sans Postmarketing Requirements
Executive Summary
Rebinyn's approval without postmarketing requirements comes as a surprise, given the advisory committee's concerns that the proposed plans weren't robust enough, as well as concerns from FDA about the treatment's safety.
You may also be interested in...
Taking Biosimilars Down A PEG: Why Copying Neulasta Isn’t So Easy
Biosimilar sponsors are 0-3 so far in attempts to win US FDA approval for copies of Amgen’s pegfilgrastim (Neulasta). FDA’s recent review of a novel clotting factor formulation offers a clue why it is turning out to be harder than it seems to copy a pegylated protein.
Taking Biosimilars Down A PEG: Why Copying Neulasta Isn’t So Easy
Biosimilar sponsors are 0-3 so far in attempts to win US FDA approval for copies of Amgen’s pegfilgrastim (Neulasta). FDA’s recent review of a novel clotting factor formulation offers a clue why it is turning out to be harder than it seems to copy a pegylated protein.
Keeping Track: First Gliomas Imaging Agent Wins Approval; Amgen Hopes New Repatha Data Boosts Prospects
The latest drug development news and US FDA highlights from our Performance Tracker.